## **Supplementary Data Table of Contents**

Supplementary Table 1. Characteristics of Included Genome-Wide Association Studies.

Supplementary Tables 2-8, 10, 11 in Excel Spreadsheet.

**Supplementary Table 2.** Supplementary Table 2. Association between T2D and Heart Failure using variants from the DIAMANTE GWAS (Vujkovic et al. Nat Genet 2020)

**Supplementary Table 3.** Association between T2D and Heart Failure using variants from the DIAGRAM GWAS (Mahajan et al. Nat Genet 2018)

**Supplementary Table 4.** Association between Insulin Resistance and Heart Failure using variants from the MAGIC GWAS (Lotta et al. Nat Genet 2017) and estimates from Wang (Diabetes Care 2017)

Supplementary Table 5. Association between Fasting Insulin and Heart Failure

Supplementary Table 6. Association between Fasting Glucose and Heart Failure

Supplementary Table 7. Association between Glycated Hemoglobin and Heart Failure

Supplementary Table 8. Association between Heart Failure and Type 2 Diabetes

Supplementary Table 9. Baseline Characteristics of GoDARTS Patients.

**Supplementary Table 10.** Leave-one-out MR analysis of association between T2D and HF using DIAMANTE variants.

Supplementary Table 11. Full Multivariable MR Results for Association of Traits with Incident HF.

**Supplementary Figure 1.** Example Power Calculations for Genetic Instruments Reflecting a Range of Different Exposure Phenotypes and their associations with HF.

**Supplementary Figure 2.** MR Plot of Single Nucleotide Variants Associated with Type 2 Diabetes and their Association with Heart Failure.

**Supplementary Figure 3.** MR Plot of Single Nucleotide Variants Associated with Insulin Resistance and their Association with Heart Failure.

**Supplementary Figure 4.** MR Plot of Single Nucleotide Variants Associated with Heart Failure and their Association with Type 2 Diabetes.

Supplementary Table 1. Characteristics of Included Genome-Wide Association Studies.

Trait	Consortium and Data Download Web Address	Author	Number of individuals	Estimate of SNP- Based Heritabili ty (where available) (%)	Quality Control
Type 2 Diabetes	DIAMANTE dbGaP - https://www.ncbi.nlm.nih. gov/gap/advanced_search/ ?TERM=phs001672.v3.p1 (data not available at time of writing but link identified in manuscript)	Vujkovic 2020	228,499 type 2 diabetes/1,1 78783 controls	19	HWE <1 × 10 <sup>-10</sup> , call rate >0.975, MAD >0.1% (European), >1% (African American, Hispanic, Asian)
Type 2 Diabetes	DIAGRAM <u>https://diagram-</u> <u>consortium.org/downloads</u> <u>.html;</u> <u>https://cnsgenomics.com/c</u> <u>ontent/data</u>	Mahajan 2018	74,124 type 2 diabetes cases/824,0 06 controls	18	<ul> <li>DIAGRAM: Call rate ≥90%; HWE p value &lt; 1 × 10<sup>-6</sup>, MAF≥ 1%</li> <li>UK Biobank data: excluded SNPs with minor allele count &lt; 5%, Hardy-Weinberg equilibrium test p value &lt; 1 × 10<sup>-6</sup>, missing genotype rate &gt; 0.05, or imputation info score &lt; 0.3.</li> </ul>
Insulin Resistance	Fasting Insulin: MAGIC <u>https://www.magicinvesti</u> <u>gators.org/downloads/</u> Triglycerides/HLD- cholesterol: GLGC <u>http://lipidgenetics.org/#d</u> <u>ata-downloads-title</u>	Lotta 2017 Wang 2017	451,193	n/a	SNPs excluded if: MAF <1%; Hardy–Weinberg equilibrium p< $1 \times 10^{-6}$ ; call rate <99%; showed differential missingness between cases and controls with p< $1 \times 10^{-6}$ ; differential genotyping between the CoreExome-24v1.0 and CoreExome- 12v1.0 chips in a subset of 96 samples genotyped using both chips.
Fasting Glucose and Fasting Insulin	MAGIC https://www.magicinvesti gators.org/downloads/	Scott 2012	133,010 (FG)	FG – 4.8 FI – 1.2	Call rate 95% and minor allele frequency (MAF) $\geq$ 1%.

			108,557 (FI)		Removed occurrences of sex discrepancies, ancestry outliers, heterozygosity, Hardy-Weinberg equilibrium $p < 1x10^{-4}$ , SNP effect estimate standard error $\ge 10$ and SNP minor allele count $< 10$ .
Glycated Haemoglobin	MAGIC https://www.magicinvesti gators.org/downloads/	Wheeler 2017	159,940	4-14	Cohorts were advised to keep SNPs with Hardy-Weinberg-disequilibrium p-value $\ge 1 \times 10^{-6}$ , SNP genotyping call rate $\ge 95\%$ and minor allele frequency (MAF) $\ge 1\%$
Heart Failure	HERMES https://www.hermesconso rtium.org/	Shah 2020	47,309 cases/930,0 14 controls	8.8	Variants removed if imputation quality < 0.5, MAF < 1%, absolute betas and s.e.> 10. More stringent QC measures applied to studies where genotyping of cases and controls was performed on different platforms.
Coronary Heart Disease	CARDIOGRAMplusC4D http://www.cardiogramplu sc4d.org/data-downloads/	Nelson 2017	10.801 cases/137,9 14controls	10.6	Call rate ≥90%; HWE p>1x10 <sup>-9</sup> ; ethnic outliers
LDL-Cholesterol	GLGC http://lipidgenetics.org/#d ata-downloads-title	Willer 2013	188,578	14.6	Average standard errors for association statistics from each study were plotted against study sample size to identify outlier studies.Allele frequencies inspected for strand orientation.Genomic control values for study specific analyses were inspected, and all were <1.20. Variants for which the minor allele was observed <7 times excluded.
Body Mass Index	GIANT <u>https://portals.broadinstitu</u> <u>te.org/collaboration/giant/i</u> <u>ndex.php/GIANT_consort</u> <u>ium_data_files</u>	Locke 2015	339,224	2.7	Predominantly call rate ≥90%; HWE p>1x10 <sup>-4</sup> ; MAF >1%
Systolic Blood Pressure	International Consortium of Blood Pressure Genome Wide Association Studies (ICBP)	Evangelou 2018 (also included data from UK BIOBANK)	1,006,863	5.7	MAF > 1%; HWE p >1x10-6; missingness < 0.015, imputation quality INFO >0.1


https://www.ebi.ac.uk/gw		
as/studies/GCST006624		


	Type 2 Diabetes	No Type 2 Diabetes	p value
	(n=8,329)	(n=4,590)	between groups
Age at recruitment (years)	65 ± 12	60 ± 12	< 0.001
Male (%)	4267 (53.5)	2386 (52.0)	< 0.001
Prior MI (%)	885 (11.1)	267 (5.8)	< 0.001
Systolic BP (mmHg)	$144\pm4$	$143 \pm 4$	< 0.001
Current/Past Smoker	3,827 (46.0)	455 (10.0)	< 0.001
Body Mass Index (kg/m <sup>2</sup> )	$30.9\pm5.8$	$29.9 \pm 5.1$	< 0.001
Aspirin use	4,111 (49.4)	996 (21.7)	< 0.001
Statin use	5,212 (62.6)	1,017 (22.2)	< 0.001
Total cholesterol (mmol/l)	$4.6\pm0.6$	$4.9\pm0.7$	< 0.001
HDL cholesterol (mmol/l)	$1.3 \pm 0.3$	$1.6\pm0.4$	< 0.001
Serum creatinine (umol/l)	$94 \pm 30$	$96 \pm 21$	0.28
Glycated haemoglobin (%)	$7.6 \pm 1.3$	$6.1\pm0.7$	< 0.001
Glycated haemoglobin (mmol/mol)	$60 \pm 14$	$43\pm8$	< 0.001

Supplementary Table 2. Baseline Characteristics of GoDARTS Patients.


Supplementary Figure 1. Example Power Calculations for Genetic Instruments Reflecting a Range of

Different Exposure Phenotypes and their associations with HF.






Supplementary Figure 2. MR Plot of Single Nucleotide Variants Associated with Type 2 Diabetes and their Association with Heart Failure.



Supplementary Figure 3. MR Plot of Single Nucleotide Variants Associated with Insulin Resistance and their Association with Heart Failure.



Supplementary Figure 4. MR Plot of Single Nucleotide Variants Associated with Heart Failure and their Association with Type 2 Diabetes.